Last edition
News about "Covid-19 vaccine Sanofi, GSK"
The Sanofi and GSK adjuvanted recombinant Covid-19 vaccine candidate achieved strong rates of neutralizing antibody responses, in line with those measured in people who have recovered from Covid-19, in all adult age groups in a phase 2 study with 722 volunteers. A global pivotal phase 3 study is expected to start in the coming weeks
Covid-19 Vaccine Sanofi, GSK | 18/05/2021 | By Darshana | 130
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members